{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:20:16Z","timestamp":1787664016784,"version":"build-2736575974"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Camlipixant is a highly selective P2X3 receptor antagonist with demonstrated efficacy in pre\u2010clinical models of evoked cough. We report the safety, tolerability, and pharmacokinetics of camlipixant in healthy participants. This Phase 1, double\u2010blind, randomized study evaluated single ascending doses (SAD; 50\/100\/200\/400\/800\/1200 mg) and multiple ascending doses (MAD; 100\/200\/400 mg, twice daily [BID]) of oral camlipixant versus placebo. Ninety participants were included (SAD n\u00a0=\u00a0 60; MAD n\u00a0=\u00a0 30). Treatment\u2010emergent adverse event (TEAE) incidence was similar between camlipixant (32\/72) and placebo (9\/18). TEAEs were mostly mild (83%), and the most common with camlipixant was dysgeusia, primarily at doses \u2265400 mg (n\u00a0=\u00a0 13), versus 50\u2013200 mg (n\u00a0=\u00a0 1). Camlipixant was rapidly absorbed (time to maximum plasma concentration SAD: 0.77\u20132.29 h; MAD: 0.50\u20132.00 h), with a short half\u2010life (SAD 4.28\u20136.71 h; MAD 7.60\u20138.39 h). In both cohorts, maximum plasma concentration (C\n                    <jats:sub>max<\/jats:sub>\n                    ) increased proportionally with dose. The area under the curve extrapolated to infinity (AUC\n                    <jats:sub>0\u2013\u221e<\/jats:sub>\n                    ) increased proportionally with dose in the SAD cohort; the increase was slightly supra\u2010proportional in the MAD cohort (steady state reached on Day 2). The geometric mean apparent volume of distribution ranged from 44.9 to 70.2 L and clearance from 5.7 to 10.4 L\/h in the SAD cohort. Pharmacokinetics were unaffected by food (geometric mean fed\/fasted ratio C\n                    <jats:sub>max<\/jats:sub>\n                    91.4% [90% confidence interval, CI, 69.8\u2013119.6]; AUC\n                    <jats:sub>0\u2013\u221e<\/jats:sub>\n                    105.5% [90% CI, 89.8\u2013124.0]). In summary, camlipixant was well tolerated, with pharmacokinetics supporting BID dosing and further clinical development for refractory chronic cough.\n                  <\/jats:p>","DOI":"10.1002\/jcph.70253","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:26:43Z","timestamp":1786451203000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, Tolerability, and Pharmacokinetics of Oral Camlipixant: A Randomized First\u2010In\u2010Human Study Using Single and Multiple Ascending Doses"],"prefix":"10.1002","volume":"66","author":[{"given":"Nathalie","family":"Chauret","sequence":"first","affiliation":[{"name":"Bellus Health  Laval Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Garceau","sequence":"additional","affiliation":[{"name":"Bellus Health  Laval Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Harvey","sequence":"additional","affiliation":[{"name":"Bellus Health  Laval Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelie","family":"Bailes","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Duncan","sequence":"additional","affiliation":[{"name":"GSK  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian","family":"McNaughton","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Zamacona","sequence":"additional","affiliation":[{"name":"GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00422-3"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.10.016"},{"key":"e_1_2_11_4_1","unstructured":"American Lung Association. Chronic cough.American Lung Association. Accessed August 11 2025.https:\/\/www.lung.org\/lung\u2010health\u2010diseases\/lung\u2010disease\u2010lookup\/chronic\u2010cough\/learn\u2010about\u2010chronic\u2010cough"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01136-2019"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-1496"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2025.07.032"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0303804"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-024-00714-1"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106726"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00089312"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60967-1"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-02171-z"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00425-2023"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.06.024"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0127-2021"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-015-9701-2"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2020.12.6.906"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2024.12.021"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-023-00666-y"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2003"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2025.2499663"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00370-w"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.653561"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.03.007"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-385526-8.00011-4"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00039.2015"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61255-1"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2013.00264"},{"issue":"1","key":"e_1_2_11_30_1","article-title":"Evaluation of the in vitro potency and selectivity of the P2X3 receptor antagonist camlipixant (BLU\u20105937)","volume":"201","author":"Filio","year":"2023","journal-title":"Lung"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202501-0093RL"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202409-1752OC"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2024.06.079"},{"key":"e_1_2_11_34_1","first-page":"1","volume-title":"US Department of Health and Human Services","author":"Center for Drug Evaluation and Research (CDER)","year":"2002"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_2_11_36_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2).2016. Accessed August 11 2025.https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-023-00621-x"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02348-5"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-022-00592-5"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70253","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:33:32Z","timestamp":1787661212000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/jcph.70253"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70253","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70253"}}